Sections
| Title | Starting Page | Number of Pages |
|---|
| COVER | 1 | 3 |
| PLUNKETT S BIOTECH &GENETICS INDUSTRY ALMANAC 2016 | 4 | 4 |
| CONTENTS | 8 | 2 |
| INTRODUCTION | 10 | 2 |
| HOW TO USE THIS BOOK | 12 | 3 |
| Chapter 1 MAJOR TRENDS AFFECTING THE BIOTECH &GENETICS INDUSTRY | 15 | 35 |
| 1) The State of the Biotechnology Industry Today | 16 | 3 |
| 2) A Short History of Biotechnology | 19 | 2 |
| 3) Ethanol Production Soared, But U.S. Federal Subsidy Expires | 21 | 1 |
| 4) Cellulosic Ethanol Makes Slow Commercial Progress | 22 | 1 |
| 5) Major Drug Companies Acquire or Partner with Smaller Biotech Firms | 23 | 1 |
| 6) From Korea to India to Singapore to China, Nations Compete Fiercely in Biotech Development | 24 | 1 |
| 7) Patients Genetic Profiles Plummet in Price as DNA Sequencing Technologies Advance | 25 | 2 |
| 8) Gene Therapies Target Defective Genes/CRISPR Advances DNA Editing | 27 | 1 |
| 9) Vaccines and Viruses in Drug Delivery | 28 | 1 |
| 10) New Blockbuster Drugs Come to Market/Drug Prices Soar/Generics Offer Some Relief | 29 | 3 |
| 11) Biotech and Orphan Drugs Create New Revenues for Drug Firms | 32 | 1 |
| 12) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce | 32 | 1 |
| 13) Drug Delivery Systems Evolve to Meet the Needs of Biotech Drugs | 33 | 1 |
| 14) Stem Cells Multiple Sources Stem from New Technologies | 34 | 2 |
| 15) Government Support for Stem Cell Research Evolves | 36 | 1 |
| 16) Stem Cells Therapeutic Cloning Techniques Advance | 37 | 1 |
| 17) Stem Cells A New Era of Regenerative Medicine Takes Shape | 38 | 1 |
| 18) Nanotechnology Converges with Biotech | 39 | 1 |
| 19) Genetically Modified (GM) Seeds and Crops/R&D Investment Is High | 40 | 2 |
| 20) Genetically Modified (GM) Ingredients in Processed or Packaged Foods | 42 | 1 |
| 21) Biopharming, Development of Transgenic, Plant-Based Pharmaceuticals | 43 | 1 |
| 22) Cloning of Farm Animals/Meat and Cheese Substitutes Created in Laboratories | 43 | 1 |
| 23) Selective Breeding, Zinc Fingers and Mutagenesis as Alternatives to GMOs | 44 | 1 |
| 24) Immunotherapy Promises New Approach to Fighting Cancers | 44 | 1 |
| 25) Technology Discussion Genes and DNA | 45 | 1 |
| 26) Technology Discussion Proteins and Proteomics | 46 | 1 |
| 27) Technology Discussion Microarrays | 46 | 1 |
| 28) Technology Discussion DNA Chips | 47 | 1 |
| 29) Technology Discussion SNPs ( Snips ) | 47 | 1 |
| 30) Technology Discussion Combinatorial Chemistry | 47 | 1 |
| 31) Technology Discussion Synthetic Biology | 48 | 1 |
| 32) Technology Discussion Recombinant DNA | 48 | 1 |
| 33) Technology Discussion Polymerase Chain Reaction (PCR) | 49 | 1 |
| Chapter 2 BIOTECH &GENETICS INDUSTRY STATISTICS | 50 | 18 |
| Biotech Industry Overview | 51 | 1 |
| The U.S. Drug Discovery &Approval Process | 52 | 1 |
| U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2014 | 53 | 1 |
| U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2014 | 54 | 1 |
| Employment in Life &Physical Science Occupations by Business Type, U.S.: May 2014 | 55 | 1 |
| Federal R&D &R&D Plant Funding for General Science &Basic Research, U.S.: Fiscal Years 2013-2015 | 56 | 1 |
| U.S. Exports &Imports of Pharmaceutical Products:2009-1st Quarter 2015 | 57 | 1 |
| U.S. Prescription Drug Expenditures, Aggregate &Per Capita Amounts, Percent Distribution: 2007-2023 | 58 | 2 |
| Prescription Drug Expenditures, U.S.: Selected Years, 1960-2023 | 60 | 1 |
| Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2014 | 61 | 1 |
| Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2014-2016 | 62 | 1 |
| Global Area of Biotech Crops by Country: 2014 | 63 | 1 |
| Domestic &Foreign Pharmaceutical Sales, PhRMA Member Companies: 1980-2014 | 64 | 1 |
| Sales By Geographic Area, PhRMA Member Companies: 2013 | 65 | 1 |
| Domestic U.S. Biopharmaceutical R&D &R&D Abroad, PhRMA Member Companies: 1980-2014 | 66 | 1 |
| Domestic U.S. Biopharmaceutical R&D &R&D Abroad Breakdown, PhRMA Member Companies: 2013 | 67 | 1 |
| Chapter 3 IMPORTANT BIOTECH &GENETICS INDUSTRY CONTACTS | 68 | 38 |
| Chapter 4 THE BIOTECH 400: WHO THEY ARE AND HOW THEY WERE CHOSEN | 106 | 419 |
| INDEX OF COMPANIES WITHIN INDUSTRY GROUPS | 107 | 9 |
| ALPHABETICAL INDEX | 116 | 3 |
| INDEX OF U.S. HEADQUARTERS LOCATION BY STATE | 119 | 3 |
| INDEX OF NON-U.S. HEADQUARTERS LOCATION BY COUNTRY | 122 | 3 |
| Individual Profiles On Each Of THE BIOTECH 400 | 125 | 400 |
| ADDITIONAL INDEXES | 525 | 24 |
| INDEX OF FIRMS NOTED AS HOT SPOTS FOR ADVANCEMENT FOR WOMEN &MINORITIES | 526 | 2 |
| INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS | 528 | 21 |
| A Short Biotech &Genetics Industry Glossary | 549 | 22 |
